Quantitative measurement properties and score interpretation of the Cough Severity Diary in patients with chronic cough.

abstract：BACKGROUND:N-chlorotaurine (NCT), a long-lived oxidant produced by human leukocytes, can be synthesized chemically and used topically as a well-tolerated antiseptic to different body regions including sensitive ones. The aim of this study was to test the tolerability of inhaled 1% NCT in aqueous solution upon repeated ...

journal_title：Therapeutic advances in respiratory disease

authors： Arnitz R,Stein M,Bauer P,Lanthaler B,Jamnig H,Scholl-Bürgi S,Stempfl-Al-Jazrawi K,Ulmer H,Baumgartner B,Embacher S,Geisler S,Gostner JM,Müllinger B,Kälz B,Nagl M

更新日期：2018-01-01 00:00:00

abstract：UNLABELLED:Alpha-1-antitrypsin deficiency [AATD] is associated with variable development of emphysema and other features of chronic obstructive pulmonary disease [COPD]. Matrix metalloproteinases [MMPs] are believed to be important in the pathophysiology of COPD, and may therefore confer susceptibility to this phenotyp...

journal_title：Therapeutic advances in respiratory disease

authors： McAloon CJ,Wood AM,Gough SC,Stockley RA

更新日期：2009-02-01 00:00:00

abstract：:There is evidence of aberrations in the vitamin D-endocrine system in subjects with respiratory diseases. Vitamin D deficiency is highly prevalent in patients with respiratory diseases, and patients who receive vitamin D have significantly larger improvements in inspiratory muscle strength and maximal oxygen uptake. S...

journal_title：Therapeutic advances in respiratory disease

authors： Luong KV,Nguyen LT

更新日期：2013-12-01 00:00:00

abstract：:To investigate whether dry powder inhalers (DPIs) function in a constrained situation, a literature analysis was performed to evaluate the use of DPIs compared with established therapies in the treatment of acute asthma and COPD, irrespective of rapid-acting beta(2)-agonist used. The external databases Medline, Embase...

journal_title：Therapeutic advances in respiratory disease

authors： Selroos O,Borgström L,Ingelf J

更新日期：2009-04-01 00:00:00

abstract：:Pulmonary arterial hypertension (PAH) is a chronic condition of elevated pulmonary arterial pressures with associated increases in pulmonary vascular resistance leading to right ventricular failure, which was almost uniformly fatal prior to the introduction of pulmonary hypertension specific therapy. Systemic prostacy...

journal_title：Therapeutic advances in respiratory disease

authors： Stream AR,Bull TM

更新日期：2012-10-01 00:00:00

abstract：BACKGROUND:Endoscopic lung volume reduction coil (LVRC) treatment is a therapeutic option for selected patients with advanced emphysema. The effects and the safety of endoscopic lung volume reduction in patients with very low forced expired volume in one second (FEV1) remain to be determined. This study was conducted t...

journal_title：Therapeutic advances in respiratory disease

authors： Simon M,Harbaum L,Oqueka T,Kluge S,Klose H

更新日期：2018-01-01 00:00:00

abstract：OBJECTIVES:Both autofluorescence imaging bronchoscopy and narrow-band imaging have shown promise in the detection of premalignant airway lesions, each by utilizing different bandwidths of lights for better characterization of the mucosal and submucosal vascular grid. Since previously published meta-analyses have shown ...

journal_title：Therapeutic advances in respiratory disease

authors： Iftikhar IH,Musani AI

更新日期：2015-10-01 00:00:00

abstract：:Chronic obstructive pulmonary disease (COPD) is a chronic condition that negatively affects several patient-centered outcomes. Among these, exercise capacity, dyspnea, and quality of life are the most relevant. In this article, factors contributing to exercise limitation, increase in exercise-induced dyspnea, quality ...

journal_title：Therapeutic advances in respiratory disease

authors： de Blasio F,Polverino M

更新日期：2012-08-01 00:00:00

abstract：BACKGROUND:Central airway obstruction (CAO) is a serious condition that affects patients with both benign and malignant diseases. Timely recognition of CAO is crucial for prompt intervention aimed at improving the symptoms and quality of life of these patients. The aim of this study is to evaluate the formal radiology ...

journal_title：Therapeutic advances in respiratory disease

authors： Harris K,Alraiyes AH,Attwood K,Modi K,Dhillon SS

更新日期：2016-04-01 00:00:00

abstract：RATIONALE:Symptom relief is a key treatment goal in patients with chronic obstructive pulmonary disease (COPD). However, there are limited data available on the response to bronchodilator therapy in patients at low risk of exacerbations with different levels of symptom severity. This study compared treatment responses ...

journal_title：Therapeutic advances in respiratory disease

authors： Vogelmeier CF,Kerwin EM,Bjermer LH,Tombs L,Jones PW,Boucot IH,Naya IP,Lipson DA,Compton C,Barnes N,Maltais F

更新日期：2020-01-01 00:00:00

abstract：:A major impediment in the development of novel drugs for chronic obstructive pulmonary disease (COPD) has been the scarcity of a well-validated, robust, and easily obtainable intermediate end point such as serum biomarkers. To date the best serum biomarkers in COPD have been non-speci"c pro-in"ammatory molecules synth...

journal_title：Therapeutic advances in respiratory disease

authors： Sin DD,Pahlavan PS,Man SF

更新日期：2008-04-01 00:00:00

abstract：:Asthma is one of the most common respiratory disorders in clinical practice, affecting up to 13% of people worldwide. Inflammation is the most important component of asthma and inhaled corticosteroids (ICS) are recommended as the first line controller treatment for patients of all ages. Treatment with corticosteroids ...

journal_title：Therapeutic advances in respiratory disease

authors： del Giudice MM,Pezzulo A,Capristo C,Alterio E,Caggiano S,de Benedictis D,Capristo AF

更新日期：2009-10-01 00:00:00

abstract：:The use of biomarkers on pleural fluid (PF) specimens may assist the decision-making process and enhance clinical diagnostic pathways. Three paradigmatic examples are heart failure, tuberculosis and, particularly, malignancy. An elevated PF concentration of the amino-terminal fragment of probrain natriuretic peptide (...

journal_title：Therapeutic advances in respiratory disease

authors： Porcel JM

更新日期：2018-01-01 00:00:00

abstract：:It is well established that smoking is the primary preventable cause of disease and death in the United States and that it is responsible for a wide range of negative health consequences, including but not limited to respiratory disease. According to the US Public Health Service, all patients attempting to quit smokin...

journal_title：Therapeutic advances in respiratory disease

authors： Hudmon KS,Corelli RL,Prokhorov AV

更新日期：2010-02-01 00:00:00

abstract：:Immunotherapy has significantly altered the treatment landscape for many cancers, including non-small cell lung cancer (NSCLC). Currently approved immuno-oncology agents for lung cancer are aimed at the reversal of immune checkpoints, programmed death protein-1 (PD-1) and programmed death ligand-1 (PD-L1). Although re...

journal_title：Therapeutic advances in respiratory disease

authors： Villanueva N,Bazhenova L

更新日期：2018-01-01 00:00:00

abstract：:Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto® or Stiolto® is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting muscarinic receptor antagonist tiotropium (TIO) and the long-acting β2-adrenocep...

journal_title：Therapeutic advances in respiratory disease

authors： Derom E,Brusselle GG,Joos GF

更新日期：2019-01-01 00:00:00

abstract：:Clinical and immunologic tolerance are hallmarks of successful allergen immunotherapy (AIT). Clinical benefits such as reduced symptoms, pharmacotherapy intake and improvement of quality of life persist following cessation of treatment. Successful AIT is associated with suppression of allergic inflammatory cells such ...

journal_title：Therapeutic advances in respiratory disease

authors： Kappen JH,Durham SR,Veen HI,Shamji MH

更新日期：2017-01-01 00:00:00

abstract：:Background We wanted to determine the impact of combined Clinical Pulmonary Infection Score (CPIS) and a spot serum procalcitonin (PCT)-guided protocol to shorten the duration of antibiotic treatment in patients with ventilator-associated pneumonia (VAP), mainly caused by nonfermentative gram-negative bacilli (NF-GNB)...

journal_title：Therapeutic advances in respiratory disease

authors： Wongsurakiat P,Tulatamakit S

更新日期：2018-01-01 00:00:00

abstract：OBJECTIVE:Our aim was to determine the influence of pulmonary rehabilitation conducted in therapeutic salt mine chambers on the functional fitness of older adults. METHODS:The study included 22 individuals of age >65 years with chronic respiratory conditions. The patients underwent the Fullerton test before and after ...

journal_title：Therapeutic advances in respiratory disease

authors： Mętel S,Kostrzon M,Adamiak J,Gattner H,Kościelecka D,Sosulska A,Szczygieł E,Golec J

更新日期：2020-01-01 00:00:00

abstract：:As our understanding of the pathobiology and natural history of the various forms of interstitial lung disease (ILD) has evolved, so have our approaches to treating this heterogeneous group of lung disorders. The earliest pharmacologic agents used to treat various forms of ILD were corticosteroids, and corticosteroids...

journal_title：Therapeutic advances in respiratory disease

authors： Kim R,Meyer KC

更新日期：2008-10-01 00:00:00

abstract：:Increased inflammatory cytokines [such as tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6)] are observed in COVID-19 patients, especially in the severe group. The phenomenon of a cytokine storm may be the central inducer of apoptosis of alveolar epithelial cells, which leads to rapid progression in severe g...

journal_title：Therapeutic advances in respiratory disease

authors： Chen XY,Yan BX,Man XY

更新日期：2020-01-01 00:00:00

abstract：:One of the great challenges of lung transplantation is to bridge the dichotomy between supply and demand of donor organs so that the maximum number of potential recipients achieve a meaningful benefit in improvements in survival and quality of life. To achieve this laudable goal is predicated on choosing candidates wh...

journal_title：Therapeutic advances in respiratory disease

authors： Mitchell AB,Glanville AR

更新日期：2019-01-01 00:00:00

abstract：:Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that can present different extrarticular manifestations involving heart, lungs and kidneys. In recent years there has been a growing awareness of the central role played by the lungs in the onset and progression of RA. In particular interstitial lung dise...

journal_title：Therapeutic advances in respiratory disease

authors： Picchianti Diamanti A,Markovic M,Argento G,Giovagnoli S,Ricci A,Laganà B,D'Amelio R

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease (ILD). Currently, two antifibrotic drugs are available for reducing forced vital capacity (FVC) decline in IPF. However, many pulmonologists wait before initiating treatment, especially when IPF patients have stable dise...

journal_title：Therapeutic advances in respiratory disease

authors： Aono Y,Nakamura Y,Kono M,Nakamura H,Yokomura K,Imokawa S,Toyoshima M,Yasui H,Hozumi H,Karayama M,Suzuki Y,Furuhashi K,Enomoto N,Fujisawa T,Inui N,Suda T

更新日期：2020-01-01 00:00:00

abstract：:Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for the treatment of ad...

journal_title：Therapeutic advances in respiratory disease

authors： Hida T

更新日期：2018-01-01 00:00:00

abstract：:Current guidelines for the management of chronic obstructive pulmonary disease (COPD) establish that bronchodilator medications are central to the symptomatic treatment of the disease. Regular treatment with long-acting bronchodilators is recommended as more effective and convenient than short-acting bronchodilators, ...

journal_title：Therapeutic advances in respiratory disease

authors： Brienza NS,Amor-Carro O,Ramos-Barbón D

更新日期：2011-02-01 00:00:00

abstract：:Bronchiectasis occurs as a result of a vicious circle consisting of an impaired mucociliary transport system, inflammation, and infection and repair of the airways. Damage to the mucociliary system prevents secretion elimination and facilitates bacterial growth and bronchial inflammation. To facilitate mucociliary cle...

journal_title：Therapeutic advances in respiratory disease

authors： Máiz Carro L,Martínez-García MA

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Bacterial pneumonia is a major cause of acute respiratory distress syndrome (ARDS) requiring extracorporeal membrane oxygenation (ECMO) support. However, it is unknown whether the type of pneumonia, community-acquired pneumonia (CAP) versus hospital-acquired pneumonia (HAP), should be considered when predict...

journal_title：Therapeutic advances in respiratory disease

authors： Park C,Na SJ,Chung CR,Cho YH,Suh GY,Jeon K

更新日期：2019-01-01 00:00:00

abstract：OBJECTIVE:Severe exacerbations in alpha-1-antitrypsin (AAT)-deficient patients with chronic obstructive pulmonary disease (COPD) and/or emphysema are a major cause of hospitalization. A multicentre, observational, retrospective study was undertaken to evaluate the effect of continuous AAT augmentation therapy in reduci...

journal_title：Therapeutic advances in respiratory disease

authors： Barros-Tizón JC,Torres ML,Blanco I,Martínez MT,Investigators of the rEXA study group.

更新日期：2012-04-01 00:00:00

abstract：BACKGROUND:Pseudomonas aeruginosa (Pa) is the predominant pulmonary pathogen in patients with cystic fibrosis (CF). Tobramycin nebulization is used for the eradication of Pa infection. Nowadays, tobramycin dry powder inhalation (DPI) is available as well. This study reports the results of eradicating Pa with tobramycin...

journal_title：Therapeutic advances in respiratory disease

authors： Akkerman-Nijland AM,Yousofi M,Rottier BL,Van der Vaart H,Burgerhof JGM,Frijlink HW,Touw DJ,Koppelman GH,Akkerman OW

更新日期：2020-01-01 00:00:00